Therapeutic area intelligence for PI3K Inhibitor with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

Roche →

Assets

Recent signals(4)

ClinicalAugust 2, 2026

Phase II Study of Alpelisib in PIK3CA-related Overgrowth Spectrum Initiated

A Phase II single-arm study is underway to evaluate the efficacy and safety of alpelisib in patients with PROS.

RegulatoryJuly 26, 2026

Genentech's ITOVEBI NDA219249 Submission Receives AP Status

The FDA has granted an Approval Pending (AP) status for Genentech's supplemental NDA for ITOVEBI (Inavolisib).

RegulatoryJuly 18, 2026

FDA Approves REVTORPYK (GEDATOLISIB) for Celcuity Inc.

The FDA has approved REVTORPYK (gedatolisib) under NDA219908 for Celcuity Inc.

RegulatoryJuly 4, 2026

FDA Accepts Supplement for Inavolisib by Genentech

The FDA has accepted a supplemental NDA for Inavolisib submitted by Genentech.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.